Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24759678 | 0.88 | NOS3 (0.39) | DHFRNOS3NOS1NOS2ALOX15 | |
| SCHEMBL22725611 | 0.81 | GABRP (0.37) | ALOX15 | |
| SCHEMBL21076527 | 0.81 | NOS3 (0.35) | DHFRNOS3NOS1NOS2ALOX15 | |
| SCHEMBL24478545 | 0.79 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL19508069 | 0.79 | P2RX3 (0.35) | DHFRNOS3NOS1NOS2ALOX15 | |
| SCHEMBL16414449 | 0.78 | DHFR (0.33) | DHFRNOS3NOS1NOS2 | |
| SCHEMBL21076466 | 0.77 | NOS3 (0.33) | NOS3NOS1NOS2ALOX15ALOX12 | |
| SCHEMBL23231054 | 0.77 | NOS3 (0.41) | NOS3NOS1NOS2ALOX15ALOX12 | |
| SCHEMBL24730694 | 0.77 | NOS3 (0.37) | DHFRNOS3NOS1NOS2ALOX15 | |
| SCHEMBL12749938 | 0.77 | NOS3 (0.55) | DHFRNOS3NOS1NOS2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | DHFR 3723/4885NOS3 1413/4885NOS1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.